News Briefing channel feed

An­tios re­port­ed­ly shut down; Clene's long-term ALS da­ta; Keytru­da, Lenvi­ma's lung can­cer fail­ures

Last year

Pad­cev, Keytru­da’s new sur­vival da­ta; Ser­ax­is rais­es $10M for di­a­betes cell ther­a­py

Last year

He­palys to de­vel­op In­ven­ti­va’s NASH treat­ment; Ever­est li­cens­es Kezar’s au­toim­mune drug

Last year

Atara to file T cell im­munother­a­py in the US in 2024; Rayze­Bio clos­es $358M IPO

Last year

Re­Code rais­es an­oth­er $50M; His­to­gen halts clin­i­cal de­vel­op­ment; 60 De­grees with­draws Covid-19 IND

Last year

Nek­tar up­dates PhIb atopic der­mati­tis da­ta amid Lil­ly suit; Cure, Frac­etat join forces on AAV plat­form

Last year

Ab­cam founder Jonathan Mil­ner op­pos­es Dana­her buy­out; First Wave tries to find new life in Sanofi drug

Last year
AI

Sor­ren­to goes to Chi­na with Covid drug; Vista­gen touts ear­ly ef­fi­ca­cy da­ta on PMDD nasal spray

Last year

Di­anthus marks Nas­daq de­but with PhI hit; Ar­bu­tus shuts oral RNA and coro­n­avirus pro­grams

Last year

En­livex halts on­col­o­gy re­search, lays off 50% of staff; Mod­er­na warns against TRC Cap­i­tal mi­ni-ten­der

Last year

ProMIS Neu­ro­sciences se­cures $20M+ PIPE; Beam Ther­a­peu­tics re­veals da­ta ahead of IND

Last year

Vaxart re­ports mixed PhII da­ta for norovirus vac­cine; J&J to pro­ceed with Cidara in­fluen­za deal 

Last year

Mer­sana CEO to step down af­ter eight years; Roy­al­ty Phar­ma pays $150M for Skytro­fa roy­al­ties

Last year

Macro­Gen­ics gets $15M from Gilead; Zenas, Bris­tol My­ers sign li­cens­ing deal in Asia-Pa­cif­ic

Last year

​​FDA to al­low 23andMe to re­port more BR­CA vari­ants; Janssen se­cures deal with AI-drug dis­cov­ery out­fit

Last year

Flag­ship re­fo­cus­es stealth RNA biotech; Mesoblast en­acts pay cuts for ex­ec­u­tives

Last year

CCM Bio­sciences breaks out of stealth with $25M; Two biotechs merge, to fo­cus on Parkin­son's

Last year

Gink­go teams up with Google Cloud; Two biotechs raise mon­ey through pri­vate place­ments

Last year

Take­da to com­mer­cial­ize Im­muno­Gen’s Ela­here in Japan; Val­ne­va shares safe­ty da­ta for its chikun­gun­ya vac­cine

Last year

Mer­ck kick-starts PhI­II cho­les­terol tri­als for its oral PC­SK9; Bax­ter re­calls 13,000+ vials of chemother­a­py

Last year

Ake­bia ex­pects to file vadadu­s­tat again to FDA by end of Q3; So­ci­etal CD­MO seeks to se­cure 8M+ in lat­est raise

Last year

Ipsen gives back Parkin­son’s drug af­ter fail­ing PhI­Ib study; Par­a­digm Ther­a­peu­tics gets glob­al rights to skin treat­ment

Last year

No­vavax says up­dat­ed Covid-19 jab works against two sub­vari­ants; Ul­ti­movacs re­vis­es PhII can­cer vac­cine read­out

Last year

FDA OKs In­grez­za for treat­ing chorea as­so­ci­at­ed with Hunt­ing­ton’s; Abi­vax inks agree­ment for up to $163M in debt fi­nanc­ing

Last year
First page Previous page 14151617181920 Next page Last page
A service from the Financial Times